From "Traveling with Children" to "A Vacation for the Whole Family": The Sanya EDITION Redefines Family Travel Experiences
SANYA, China, June 30, 2026 /PRNewswire/ -- As family travel continues to evolve, the concept of a family vacation is shifting from simply traveling with children to creating meaningful experiences for every family member. Today's families...
Hoymiles Presents Full-Scenario Energy Solutions and Expands Strategic Partnerships at Intersolar Europe 2026
MUNICH, June 26, 2026 /PRNewswire/ -- Hoymiles, a global leader in smart energy solutions, presented its comprehensive open-energy ecosystem at Intersolar Europe 2026. Building on its world-renowned microinverter expertise, the company officially...
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed...
Shanghai Electric Presents Full-Chain Collaborative Solutions for Zero-Carbon Transition at Carbon Neutrality Expo 2026
SHANGHAI, June 16, 2026 /PRNewswire/ -- Shanghai Electric ("the Company") (SEHK: 02727, SSE: 601727) has successfully concluded its exhibition at the 2026 Shanghai International Carbon Neutrality Expo in Technologies, Products and Achievements...
Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye disease At 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a 76% proptosis response at Week 24 in chronic TED...
Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following...
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several...
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
TWSC Presents Full-Stack Storage Solutions at COMPUTEX 2026 to Meet Diverse Demands of "AI Together" Scenarios
TAIPEI, June 3, 2026 /PRNewswire/ -- COMPUTEX 2026 opened in Taipei on June 2 under the theme "AI Together". TWSC showcased its full-stack AI storage solutions to demonstrate systematic storage competence covering data centers, smart terminals and...
Topband New Energy Presents Ecosolex C&I Storage Portfolio for the Flexibility Era at SNEC 2026
Built for industrial parks, factories and commercial facilities, the portfolio combines liquid-cooled energy storage, flexible system architectures and cloud-based management to support smarter energy flexibility for global businesses. SHENZHEN,...